Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from CareDx ( (CDNA) ).
On October 22, 2025, CareDx, Inc. appointed Suresh Gunasekaran as a Class II director. Mr. Gunasekaran, with extensive experience in healthcare leadership, will receive compensation in cash and restricted stock units as part of his non-employee director role. This appointment may enhance CareDx’s strategic direction and governance with Mr. Gunasekaran’s expertise.
The most recent analyst rating on (CDNA) stock is a Hold with a $15.50 price target. To see the full list of analyst forecasts on CareDx stock, see the CDNA Stock Forecast page.
Spark’s Take on CDNA Stock
According to Spark, TipRanks’ AI Analyst, CDNA is a Neutral.
CareDx’s overall stock score reflects a balanced outlook. The most significant strengths are the strong earnings call performance and reasonable valuation. However, mixed financial performance and potential policy impacts present risks. Technical indicators suggest a neutral to slightly positive trend.
To see Spark’s full report on CDNA stock, click here.
More about CareDx
CareDx, Inc. operates in the healthcare industry, focusing on providing diagnostic solutions for transplant patients. The company offers products and services designed to improve the quality of life for transplant recipients, with a market focus on innovative testing and monitoring technologies.
Average Trading Volume: 1,343,069
Technical Sentiment Signal: Sell
Current Market Cap: $775.8M
Learn more about CDNA stock on TipRanks’ Stock Analysis page.